Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.
about
Pituitary somatostatin receptor signalingAdvancing Treatment of Pituitary Adenomas through Targeted Molecular Therapies: The Acromegaly and Cushing Disease ParadigmsPasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Medical treatment of Cushing's disease: Overview and recent findings.Update on medical treatment for Cushing's disease.The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapyCushing's syndrome: epidemiology and developments in disease management.Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice GuidelineMifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.Peptide receptor targeting in cancer: the somatostatin paradigm.The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study.A survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran.Drugs in the medical treatment of Cushing's syndrome.The somatostatin receptor subtype 5 in neuroendocrine tumours.Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate.Recent developments in drug therapy for Cushing's disease.Molecular basis of pharmacological therapy in Cushing's disease.Emerging drugs for Cushing's disease.Cushing's syndrome: an update on current pharmacotherapy and future directions.USP8: a novel therapeutic target for Cushing's disease.Temozolomide-Induced Shrinkage of Invasive Pituitary Adenoma in Patient with Nelson's Syndrome: A Case Report and Review of the Literature.Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells.Antiproliferative effects of somatostatin analogs in endocrine tumours.New treatment guidelines on Cushing's disease.Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy.Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclatureEndocrine DisordersDopamine Agonists for Pituitary Adenomas
P2860
Q24631604-A08DE820-CA44-4C10-A33F-BA4E8135B164Q26741707-1797CCEC-DDDC-47A6-9DBA-1583A9D5367CQ33163578-CDC43990-B8FE-4B5B-A764-751AC3DA58C6Q33579615-D6099B21-A5B9-4D27-9FB1-CFA92126A221Q33735039-2C742799-F4F9-4EA7-80A2-D7748DE32979Q33802284-9031D5E9-7D77-4143-B726-722914971AF6Q34467881-B9F15239-0E23-4992-8C12-CB207F711625Q35531889-644E417C-80D8-4984-8516-E0C5FECB05B4Q35744515-4F84EC48-7A80-44AC-B374-5241BC5885F5Q35916555-5260FC75-C3C5-45C4-BDAD-4B9163B92639Q36637525-D52C06C8-E6AC-4161-AD1B-DE35CDE5602BQ36638046-C74DEE81-C11B-46FB-B6A9-7F7AAFB533B9Q36681083-7C051E26-9ECE-4276-97AE-55D702CF922FQ36983219-D5713351-8254-4B82-B8D6-85283F3773DDQ37638759-4B646233-776E-45D9-9732-3DF1A5C51F10Q37691450-73A4A5C6-FD11-42E7-B402-A0BB2D2AC5DEQ37802798-23DA303E-5B47-425D-BFDB-1000127D3A54Q37873797-AB38BAD4-53A4-43F3-A0D9-7A4B5198D479Q38112082-9B71E669-34FB-47EC-BBFE-4D6BF4219A9AQ38165863-E6C3E157-021A-40D8-B389-92696C577C33Q38505947-B4925882-F3CB-4574-88E6-BDAE4041D9B6Q38541695-46338B0D-04C3-4282-A9FD-D01FABA77BAEQ38545050-0ACD0261-A88F-4DFB-AB35-207354E855C1Q38556703-E7695179-3F3B-4473-81CD-D184F12910F1Q39333836-D543843B-FBA4-4BD7-89E4-EE855613C6E5Q40014468-6DDF2949-389E-45B6-9EFA-9361868CC489Q42154119-20F5ACF6-D29F-4CAF-A44A-1B5D7F51B7EFQ42290533-47A8A63E-EEBB-4E9A-BBB0-68AA8D0A1737Q48339564-26834F8D-523A-446A-A6BC-0CF70FA7F9F7Q54360050-755D4B96-2D7B-4D59-B621-7E780E3E126AQ57144951-A1D3DB3A-0061-4641-A218-78E4B5114973Q57765055-0D29B475-4C9B-4558-9AF9-BEE89F2BA8B8Q58729410-331F2E30-3F61-45A0-BBF3-438A3634643F
P2860
Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.
@en
type
label
Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.
@en
prefLabel
Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.
@en
P2093
P356
P1476
Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas
@en
P2093
Aart-Jan van der Lelij
Christiaan de Bruin
Diane M Sprij-Mooij
Ferdinand Roelfsema
Johannes A Romijn
Leo J Hofland
Maarten O van Aken
Richard A Feelders
Steven W J Lamberts
P304
P356
10.1210/JC.2008-2101
P407
P577
2009-01-13T00:00:00Z